pharmaceutical composition comprising cannabidivarine phytocannabinoids (cbdv) and cannabidiol (cbd)

摘要

Summary pharmaceutical composition comprising the cannabidivarine (cbdv) and cannabidiol (cbd) phytocannabinoids This invention relates to a pharmaceutical composition comprising or consisting essentially of the cannabidivarine (cbdv) and cannabidiol (cbd) phytocannabinoids. The composition is particularly safe and effective for use in the treatment of neurological conditions characterized by central nervous system hyperexcitability, spasms or convulsions such as those occurring in epilepsy. preferably cbdv and cbd are present with at least one non-cannabinoid cannabis component, such as one or more terpenes or a terpene moiety. more particularly, the composition further comprises one or more cannabicromene-type compounds. particularly propyl variant cannabicromene (cbcv) and / or cannabichromene (cbc). more particularly, the composition is absent or substantially absent from other cannabinoids, including, in particular, tetrahydrocannabinol (thc) and tetrahydrocannabivarin (thcv), which would normally be present in significant amounts in cannabis chemotypes designed to contain a significant amount of cbdv and / or cbd.